Immunovant’s Treatment for Eye Disease Fails in Late-stage Trials

by Medscape • 2026/04/02 • 0 Comments

Immunovant said on Thursday that its therapy failed to reduce eye bulging ⁠when tested in patients with moderate-to-severe thyroid eye disease in two late-stage...
Reuters Health Information

← The price of being in our profession comes with responsibility

Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration →